A5085689787- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Prostate Cancer Treatment and Research
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Lipoproteins and Cardiovascular Health
- Economic and Financial Impacts of Cancer
- CAR-T cell therapy research
- Statistical Methods in Clinical Trials
- Prostate Cancer Diagnosis and Treatment
- Pharmaceutical Economics and Policy
- Lung Cancer Research Studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- DNA Repair Mechanisms
- Nonmelanoma Skin Cancer Studies
- Global Cancer Incidence and Screening
- Hedgehog Signaling Pathway Studies
- Advanced Radiotherapy Techniques
- Workplace Health and Well-being
Regeneron (United States)
2021-2025
Pfizer (United States)
2018-2021
Amgen (United States)
2014-2017
American Cancer Society
2013-2015
Emory University
2013-2015
GlaxoSmithKline (United States)
2011
South College
2011
Imperial College London
2008
The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations BRCA1 BRCA2 ( BRCA1/2).We conducted a randomized, open-label, phase 3 trial which BRCA1/2 mutation were assigned, 2:1 ratio, to receive (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, vinorelbine continuous 21-day cycles). primary end point was progression-free survival,...
In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P < 0.0001) and improved patient-reported outcomes (PRO) in germline BRCA1/2 (gBRCA1/2)-mutated advanced breast cancer (ABC). We report final overall (OS).This randomized phase III trial enrolled patients with gBRCA1/2-mutated HER2-negative ABC. Patients received or physician's choice of chemotherapy. OS was analyzed using stratified HR log-rank...
Abstract First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free (PFS) versus chemotherapy patients with advanced non-small lung cancer (aNSCLC) PD-ligand 1 (PD-L1) expression ≥50%. EMPOWER-Lung 3 ( NCT03409614 ), a double-blind, placebo-controlled, phase study, examined plus platinum-doublet as first-line treatment for aNSCLC, irrespective of PD-L1 or histology. In this 466 stage...
EMPOWER-Lung 3 part 2 (NCT03409614), a double-blind, placebo-controlled phase study, investigated cemiplimab (antiprogrammed cell death protein 1) plus chemotherapy versus placebo in patients with advanced NSCLC without EGFR, ALK, or ROS1 aberrations, either squamous nonsquamous histology, irrespective of programmed death-ligand 1 levels. At primary analysis, after 16.4 months follow-up, improved median overall survival (OS) alone (21.9 13.0 mo, hazard ratio [HR] = 0.71, 95% confidence...
In the EMBRACA phase III trial, talazoparib (1 mg daily, orally) demonstrated a statistically significant improvement in PFS versus physician's choice of chemotherapy (PCT; capecitabine, eribulin, gemcitabine, or vinorelbine) patients with HER2-negative advanced breast cancer carrying germline BRCA1/2 mutation; we evaluated patient-reported outcomes (PROs).Patients were randomized 2 : 1 to receive PCT. PROs assessed at day (baseline), start each treatment cycle (every 3 weeks), and end...
Diffuse large B-cell lymphoma (DLBCL) and follicular (FL) treatments have been rapidly evolving for patients treated in later lines of therapy (LoT). Country-specific cancer registry data the US Western Europe (WE) were combined with physician survey results to project incidence, prevalence, number DLBCL FL eligible by LoT between 2020 2025. The total incidents prevalent cases is expected increase 2025 WE. 56% 53% third line plus (3L+) 60% 55% initiated treatment WE, respectively. Further...
Abstract Background In the EMBRACA phase III study (NCT01945775), talazoparib was associated with a significantly prolonged progression-free survival (PFS) compared physician's choice of chemotherapy (PCT) in germline BRCA1/2-mutated HER2-negative advanced breast cancer (ABC). Herein, safety profile is explored detail. Materials and Methods Overall, 412 patients received ≥1 dose (n = 286) or PCT 126). Adverse events (AEs) were evaluated, including timing, duration, potential overlap selected...
The high acute costs of cardiovascular disease and events are well established, particularly in terms direct medical costs. associated with lost work productivity have been described a broad sense, but little is known about workplace absenteeism or short term disability among risk patients. objective this study was to quantify (WA) short-term (STD) hours related clinical procedures (CVERP) United States employees risk.Medical, WA and/or STD data from the Truven Health MarketScan® Research...
Annual direct costs for cardiovascular (CV) diseases in the United States are approximately $195.6 billion, with many high-risk patients remaining at risk major events (CVE). This study evaluated clinical and economic burden associated new CVE up to 3 years post-event among hyperlipidemia. Hyperlipidemic a primary inpatient claim (myocardial infarction, unstable angina, ischemic stroke, transient attack, coronary artery bypass graft, percutaneous intervention heart failure) were identified...
Patients diagnosed with metastatic basal cell carcinoma (BCC) have a poor prognosis. The current standard of care for adults locally advanced or BCC who are not candidates surgery radiation therapy is treatment hedgehog pathway inhibitors (HHIs). For patients progress while on this therapy, further options limited. There also need real-world clinical practice data the characteristics, management, disease progression, and survivorship these patients. ongoing CemiplimAb-rwlc Survivorship...
The current study was performed to describe patient characteristics, treatment patterns, survival, health care resource use (HRU), and costs among older women in the United States with advanced (American Joint Committee on Cancer stage III/IV) triple-negative breast cancer (TNBC) Surveillance, Epidemiology, End Results (SEER)-Medicare database.Women who were aged ≥66 years at time of diagnosis diagnosed TNBC between January 1, 2007, 2011, SEER-Medicare database followed for survival through...
Abstract Background Talazoparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that causes death in cells with breast cancer susceptibility gene 1 or 2 (BRCA1/2) mutations. Methods EMBRACA (NCT01945775) was randomized phase III study comparing efficacy, safety, and patient-reported outcomes (PROs) of talazoparib (1 mg) physician’s choice chemotherapy (PCT: capecitabine, eribulin, gemcitabine, vinorelbine) locally advanced metastatic germline BRCA1/2 (gBRCA1/2) mutation....
Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin's (NHL), characterized by a long natural course remissions/relapses. We aimed to evaluate real-world quality life (QoL) in patients with FL, line therapy (LOT), and across countries. Data were drawn from the Adelphi FL Disease Specific Programme™, cross-sectional survey physicians their Europe [France, Germany, Italy, Spain, United Kingdom (UK)], States (US) June 2021 January 2022. Patients provided demographics patient-reported...
ABSTRACT Background The value of lipoprotein(a) (Lp[a]) for predicting cardiovascular disease ( CVD ) across low‐density lipoprotein cholesterol LDL ‐C) is uncertain. Hypothesis In older high‐risk adults, higher and Lp(a) combined would be associated with risk more healthcare costs. Methods We included 3251 subjects (prior , diabetes, or 10‐year Framingham >20%) age ≥65 years from the Cardiovascular Health Study examined relation tertiles incident coronary heart CHD ), all‐cause mortality...
Background: Trends/outcomes associated with National Comprehensive Cancer Network (NCCN)-recommended biomarker testing to guide advanced non-small-cell lung cancer (aNSCLC) treatment were assessed. Methods: Patients initiating first-line aNSCLC included using a nationwide electronic health record-derived database (1/1/2015-10/31/2021). Trends in pre-first-line (PD-L1, major genomic aberrations), factors and associations between outcomes Results: PD-L1/genomic aberration rates increased from...